Risedronate Sodium Tablet, Film Coated
Product Images NDC 60723-041

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Risedronate Sodium (NDC 60723-041). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image Description (Carton 12 Ct)

Image Description (Carton 12 Ct)
This is a description of a medication called "Once-a-Week" with the NDC (National Drug Code) number 60723-041-12. The medication contains 35mg of Risedronate Sodium and is in tablet form. The package contains a 12-week supply and each unit contains 4 tablets. There are instructions on how to take the medication, but there is some gibberish mixed in due to (Optical Character Recognition) errors.*
FDA Label Image

Image Description (Carton 4 Ct)

Image Description (Carton 4 Ct)
Risedronate Sodium Tablets, USP are recommended for the treatment of osteoporosis. The medication guide enclosed in the package should be dispensed to each patient. This is a 4 Week Supply of Rx only 414 Unit of Use Tablets. The text does not provide more information, as some characters are unreadable.*
FDA Label Image

Image Description (Figure 1)

Image Description (Figure 1)
FDA Label Image

Image Description (Figure 2)

Image Description (Figure 2)
The text describes a figure (Figure 2) showing the change in BMD (bone mineral density) from baseline in a study about prevention over the course of 2 years. The BMD data is displayed in the form of a graph with mean % change and standard error (SE) values. The figure includes data points for the lumbar spine, femoral neck, and trochanter. However, due to errors, some of the text appears nonsensical (e.g. "o] ClPecsbo W risearonae soaum").*
FDA Label Image

Image Description (Figure 3)

Image Description (Figure 3)
This appears to be a figure from a study showing the change in bone mineral density (BMD) from baseline in patients who recently initiated glucocorticoid therapy. The figure compares the changes observed with placebo, Risedronate Sodium 5 mg, and other treatments. The BMD changes are shown for different parts of the body including the lumbar spine, femoral neck, and trochanter.*
FDA Label Image

Image Description (Figure 4)

Image Description (Figure 4)
The text describes a figure (Figure 4) that shows the change in bone mineral density (BMD) from baseline in patients on long-term glucocorticoid therapy. The figure displays BMD data for a placebo group and a group taking Risedronate Sodium 5mg. The BMD values are provided for lumbar spine, femoral neck, and trochanter. SE is also mentioned in the figure.*
FDA Label Image

Image Description (Figure 5)

Image Description (Figure 5)
The text is a table or figure and does not provide a useful description.*
FDA Label Image

Image Description (Figure 6)

Image Description (Figure 6)
FDA Label Image

Image Description (Risedronate Sodium)

Image Description (Risedronate Sodium)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.